LLY needs just 9% to reach $1,200, a figure that sits below the 90%-confidence base case target of $1,280 despite 55% revenue growth.
Foundayo signed up 8,000+ prescribers with 80% of scripts new-to-class, while retatrutide's Phase 3 showed 25 to 37 pounds of weight loss.
Act now: the ****** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Eli Lilly (NYSE:LLY) just reported a quarter that should have sent bulls into a frenzy. Revenue grew 55.5% year over year to $19.80 billion, Mounjaro alone delivered $8.66 billion, and management raised full-year guidance to $82 to $85 billion.
Yet shares are up just 2.57% year to date at $1,098.57. That disconnect is the entire setup for my question: can LLY trade at $1,200 by year-end 2026? I think it can, and the math is closer than most realize.
Foundayo signed up 8,000+ prescribers with 80% of scripts new-to-class, while retatrutide's Phase 3 showed 25 to 37 pounds of weight loss.
Act now: the ****** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Eli Lilly (NYSE:LLY) just reported a quarter that should have sent bulls into a frenzy. Revenue grew 55.5% year over year to $19.80 billion, Mounjaro alone delivered $8.66 billion, and management raised full-year guidance to $82 to $85 billion.
Yet shares are up just 2.57% year to date at $1,098.57. That disconnect is the entire setup for my question: can LLY trade at $1,200 by year-end 2026? I think it can, and the math is closer than most realize.
4 months ago
